Senetek PLC Acquires New Cytokinin Patents to Include Enhanced Skin Care Indications and New Systemic Use Applications
Thursday January 23, 11:50 am ET
NAPA, Calif., Jan. 23 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News), ( www.senetekplc.com ), announced today that it has acquired additional patent rights for the systemic uses of Cytokinins to include injection therapy along with the expanded indication for inflammatory diseases. The Company has successfully built a distribution network with major market leaders in various channels of distribution including ICN Pharmaceuticals, Revlon Inc., The Body Shop, Shaklee Corporation and Enprani for its lead Cytokinin, Kinetin.
Dr. Michael DelMage, Senetek's Chief Technical Officer, said, "This acquisition is the beginning of the enhancement of our patent portfolio and increasing the value of our technology. This allows us to increase our Kinetin product offerings for treatment and use beyond anti-aging of the skin."
Senetek PLC is a healthcare technologies company focused on developing and co-marketing products applicable to the anti-aging markets in key skin care/dermatologicals and sexual dysfunction categories worldwide.
Visit Senetek PLC's web site: senetekplc.com .
Senetek PLC Investor Relations Contact:
1-707-226-3900 ext. 102
E-Mail: Pknopick@eandecommunications.com
Safe Harbor Statement:
This news release may contain statements that may be considered "forward-looking statements" under the Federal securities laws, including statements concerning the revenue and licensing income the Company may receive in the future under licenses of the Company's products, and the additional licensing agreements the Company may enter into during 2003. No forward-looking statement the Company makes is a guarantee of future performance or events. Actual results or events may differ materially from those in the forward-looking statements as a result of various factors, including the risks and uncertainties described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 and Quarterly Report on Form 10-Q for the three months ended September 30, 2002, filed with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Senetek PLC |
